At AlgoDx, the premise underlying all our research is the final product’s reliability. Our research methods are based on gold standards used in medical device and pharmaceutical development. We use a scientific, evidence-based approach with regulatory requirements in mind.
NAVOY® product suite
The NAVOY® portfolio includes machine learning algorithms intended to assist clinical decision support in intensive care. Developed for conditions with high unmet medical need, these algorithms are designed to generate robust clinical evidence for product claims, covering clinical and health-economic benefits as well as potential risks.
AlgoDx intensive care proprietary pipeline as of July 2022
|
Pre-clinical R&D |
Regulatory clearance EU & US |
Clinical validation in intensive care |
Post-marketing clinical follow-up |
|
|---|---|---|---|---|
| NAVOY® Sepsis |
||||
| NAVOY® Acute Kidney Injury |
||||
| Undisclosed Therapeutic Indication | ||||
|
Ongoing
Complete |
||||
Clinical trials – AlgoDx sponsored clinical research
For more information on our ongoing clinical projects in intensive care, visit clinicaltrials.gov
ExPRESS
Early Prediction of Sepsis in Hospitalized Patients Using a Machine Learning Algorithm, a Randomized Clinical Validation Trial.
Protocol number: NCT04570618
GENIUS
Integration and Evaluation of a Machine Learning Algorithm for Sepsis Prediction in an Electronic Health Record System – a Prospective Observational Study.
Protocol number: NCT05095220
AKI-SE-02
Clinical validation of NAVOY® Acute Kidney Injury in ICU patients.
Protocol number: NCT05424874
AlgoDx products in the clinical workflow – case study: NAVOY® Sepsis